$IONS
IONIS PHARMACEUTICALS INC Stock $ions

$ions Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-Q Financial Statement

#000110465913081234 Filed on November 05, 2013

Income Statement

Concept	2013 Q4	2013 Q3	2012 Q3
Revenue	$42.25M	$23.59M	$11.60M
YoY Change	112.59%	103.3%	-43.99%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.700M	$3.400M	$3.100M
YoY Change	46.88%	9.68%	0.0%
% of Gross Profit
Research & Development	$57.40M	$45.00M	$35.60M
YoY Change		26.4%	-10.83%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$62.11M	$49.09M	$39.65M
YoY Change	35.04%	23.82%	-7.86%
Operating Profit	-$19.86M	-$25.51M	-$28.05M
YoY Change	-23.97%	-9.06%	25.68%
Interest Expense	-$3.900M	$4.867M	$5.937M
YoY Change	-125.83%	-18.02%	24.39%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$23.80M	-$29.76M	-$38.35M
YoY Change	-90.18%	-22.38%	42.64%
Income Tax	$500.0K	-$5.200M	-$706.0K
% Of Pretax Income
Net Earnings	-$24.30M	-$24.60M	-$37.60M
YoY Change	-89.62%	-34.57%	39.78%
Net Earnings / Revenue	-57.52%	-104.3%	-324.11%
Basic Earnings Per Share
Diluted Earnings Per Share	-$209.1K	-$213.4K	-$0.37
COMMON SHARES
Basic Shares Outstanding	116.1M shares	115.3M shares	100.7M shares
Diluted Shares Outstanding		115.3M shares	100.7M shares

Balance Sheet

Concept	2013 Q4	2013 Q3	2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$656.8M	$670.9M	$343.6M
YoY Change	75.4%	95.27%	-5.82%
Cash & Equivalents	$160.0M	$256.4M	$84.56M
Short-Term Investments	$496.8M	$414.5M	$259.0M
Other Short-Term Assets	$7.518M	$7.372M	$7.800M
YoY Change	-13.85%	-5.49%	2.63%
Inventory	$8.000M	$7.400M	$6.700M
Prepaid Expenses
Receivables	$11.10M	$12.60M	$3.500M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$735.5M	$763.3M	$361.6M
YoY Change	73.7%	111.1%	-4.11%
LONG-TERM ASSETS
Property, Plant & Equipment	$86.20M	$87.27M	$92.60M
YoY Change	-5.36%	-5.75%	-5.51%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			-$5.563M
YoY Change
Other Assets	$5.400M	$5.500M	$6.100M
YoY Change	-8.47%	-9.84%	96.77%
Total Long-Term Assets	$111.6M	$118.6M	$124.1M
YoY Change	-8.67%	-4.43%	-3.56%
TOTAL ASSETS
Total Short-Term Assets	$735.5M	$763.3M	$361.6M
Total Long-Term Assets	$111.6M	$118.6M	$124.1M
Total Assets	$847.2M	$881.9M	$485.7M
YoY Change	55.25%	81.58%	-3.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.01M	$8.781M	$5.256M
YoY Change	7.52%	67.07%	-21.55%
Accrued Expenses	$22.09M	$22.28M	$11.90M
YoY Change	43.45%	87.25%	-41.38%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.400M	$4.600M	$5.200M
YoY Change	-10.2%	-11.54%	23.81%
Total Short-Term Liabilities	$97.81M	$103.3M	$51.60M
YoY Change	31.61%	100.15%	-38.2%
LONG-TERM LIABILITIES
Long-Term Debt	$228.2M	$226.2M	$221.3M
YoY Change	2.84%	2.21%	3.95%
Other Long-Term Liabilities	$142.8M	$151.0M	$42.50M
YoY Change	114.09%	255.29%	88.05%
Total Long-Term Liabilities	$371.0M	$377.2M	$263.8M
YoY Change	28.55%	42.99%	12.02%
TOTAL LIABILITIES
Total Short-Term Liabilities	$97.81M	$103.3M	$51.60M
Total Long-Term Liabilities	$371.0M	$377.2M	$263.8M
Total Liabilities	$468.8M	$480.5M	$315.4M
YoY Change	29.17%	52.33%	-1.13%
SHAREHOLDERS EQUITY
Retained Earnings	-$967.6M	-$943.3M	-$904.3M
YoY Change	6.69%	4.31%
Common Stock	$1.325B	$1.316B	$1.074B
YoY Change	22.99%	22.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$378.4M	$401.4M	$170.3M
YoY Change
Total Liabilities & Shareholders Equity	$847.2M	$881.9M	$485.7M
YoY Change	55.25%	81.58%	-3.97%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2012 Q3
OPERATING ACTIVITIES
Net Income	-$24.30M	-$24.60M	-$37.60M
YoY Change	-89.62%	-34.57%	39.78%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$14.50M	$65.80M	-$24.90M
YoY Change	-140.17%	-364.26%	7.33%
INVESTING ACTIVITIES
Capital Expenditures	-$500.0K	-$500.0K	-$100.0K
YoY Change	0.0%	400.0%	-96.55%
Acquisitions
YoY Change
Other Investing Activities	-$84.90M	-$122.7M	-$10.40M
YoY Change	-1643.64%	1079.81%	285.19%
Cash From Investing Activities	-$85.20M	-$123.4M	-$10.60M
YoY Change	-1804.0%	1064.15%	85.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.300M	17.40M	34.40M
YoY Change	-375.0%	-49.42%	-3922.22%
NET CHANGE
Cash From Operating Activities	-14.50M	65.80M	-24.90M
Cash From Investing Activities	-85.20M	-123.4M	-10.60M
Cash From Financing Activities	3.300M	17.40M	34.40M
Net Change In Cash	-96.40M	-40.20M	-1.100M
YoY Change	-341.6%	3554.55%	-96.31%
FREE CASH FLOW
Cash From Operating Activities	-$14.50M	$65.80M	-$24.90M
Capital Expenditures	-$500.0K	-$500.0K	-$100.0K
Free Cash Flow	-$14.00M	$66.30M	-$24.80M
YoY Change	-138.25%	-367.34%	22.17%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	172000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	1335000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2035000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-122000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2207000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1616000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	74322000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax	1400000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax	11400000	USD
CY2013Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2812000	USD
CY2012Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2034000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8318000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6761000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Before Reclassifications Before Tax OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax	2207000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Loss Before Reclassifications Before Tax OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax	-122000	USD
	us-gaap	Other Comprehensive Income Loss Before Reclassifications Before Tax OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax	17876000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Use of estimates</font></b></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</font></p> </div>
	us-gaap	Other Comprehensive Income Loss Before Reclassifications Before Tax OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax	1616000	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	66656000	USD
	isis	Licensing And Royalty Revenue LicensingAndRoyaltyRevenue	2091000	USD
	us-gaap	Revenues Revenues	82176000	USD
	dei	Entity Registrant Name EntityRegistrantName	ISIS PHARMACEUTICALS INC
CY2013Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	7385000	USD
	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	60500000	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	441000	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	664000	USD
CY2012Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	6121000	USD
CY2013Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	9617869	shares
CY2013Q2	us-gaap	Share Price SharePrice	19.00
CY2013Q2	isis	Sale Of Stock Number Of Shares Issued At Over Allotment Option SaleOfStockNumberOfSharesIssuedAtOverAllotmentOption	617869	shares
CY2013Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	173200000	USD
CY2013Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9500000	USD
	isis	Variable Interest Entity Not Primary Beneficiary Number Of Entities VariableInterestEntityNotPrimaryBeneficiaryNumberOfEntities	5	entity
CY2012	isis	Variable Interest Entity Not Primary Beneficiary Number Of Entities VariableInterestEntityNotPrimaryBeneficiaryNumberOfEntities	6	entity
CY2013Q3	us-gaap	Variable Interest Entity Nonconsolidated Carrying Amount Assets VariableInterestEntityNonconsolidatedCarryingAmountAssets	66800000	USD
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	26986000	USD
CY2012Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	968000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	12480000	USD
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-770000	USD
CY2012Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	846000	USD
CY2013Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	29021000	USD
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35600000	USD
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3096000	USD
CY2013Q3	isis	Available For Sale Securities Debt Maturities Within One Year Percentage AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage	0.39	pure
CY2013Q3	isis	Available For Sale Securities Debt Maturities After One Through Two Years Percentage AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage	0.42	pure
CY2013Q3	isis	Available For Sale Securities Debt Maturities After Two Through Three Years Percentage AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeYearsPercentage	0.19	pure
CY2013Q3	isis	Available For Sale Securities Debt Maturities Total Percentage AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage	1.00	pure
CY2013Q3	isis	Available For Sale Securities Debt Maturities Within Two Years Percentage AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage	0.81	pure
CY2013Q3	isis	Number Of Privately Held Companies In Which Entity Has Equity Investment NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment	3	entity
CY2013Q3	isis	Number Of Publicly Held Companies In Which Entity Has Equity Investment NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment	3	entity
CY2012Q4	us-gaap	Cost Method Investments CostMethodInvestments	625000	USD
CY2012Q4	us-gaap	Cost Method Investments Fair Value Disclosure CostMethodInvestmentsFairValueDisclosure	625000	USD
CY2013Q3	us-gaap	Cost Method Investments CostMethodInvestments	625000	USD
CY2013Q3	us-gaap	Cost Method Investments Fair Value Disclosure CostMethodInvestmentsFairValueDisclosure	625000	USD
CY2013Q3	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	145	security
CY2013Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	243690000	USD
CY2013Q3	isis	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses Accumulated In Investments AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLossesAccumulatedInInvestments	601000	USD
CY2013Q3	isis	Fair Value Assets Transfer Between Level1 And Level2 Amount FairValueAssetsTransferBetweenLevel1AndLevel2Amount	0	USD
CY2012Q3	isis	Fair Value Assets Transfer Between Level1 And Level2 Amount FairValueAssetsTransferBetweenLevel1AndLevel2Amount	0	USD
	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	-6437000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	11400000	USD
CY2013Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	414490000	USD
CY2013Q3	us-gaap	Receivables Long Term Contracts Or Programs ReceivablesLongTermContractsOrPrograms	12645000	USD
	dei	Entity Central Index Key EntityCentralIndexKey	0000874015
	dei	Document Period End Date DocumentPeriodEndDate	2013-09-30
	dei	Amendment Flag AmendmentFlag	false
CY2013Q3	isis	Significant Equity Investment SignificantEquityInvestment	65004000	USD
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2013Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	116074372	shares
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	124482000	USD
CY2012Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	249964000	USD
CY2012Q4	us-gaap	Receivables Long Term Contracts Or Programs ReceivablesLongTermContractsOrPrograms	522000	USD
CY2012Q4	isis	Significant Equity Investment SignificantEquityInvestment	33622000	USD
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	8727000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	423438000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	91084000	USD
CY2012Q4	isis	Licenses Net LicensesNet	6579000	USD
CY2012Q4	isis	Patents Net PatentsNet	18646000	USD
CY2012Q4	isis	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	5939000	USD
CY2012Q4	us-gaap	Assets Assets	545686000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10239000	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7878000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15401000	USD
CY2012Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	4879000	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	35925000	USD
CY2012Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	143990000	USD
CY2012Q4	isis	Capital Lease And Other Long Term Borrowings Non Current CapitalLeaseAndOtherLongTermBorrowingsNonCurrent	7402000	USD
CY2012Q4	isis	Long Term Financing Obligation LongTermFinancingObligation	70550000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	362920000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	102000	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1077150000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-906966000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	182766000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	545686000	USD
CY2013Q3	us-gaap	Assets Assets	881916000	USD
CY2013Q3	us-gaap	Assets Current AssetsCurrent	763304000	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	103278000	USD
CY2013Q3	us-gaap	Liabilities Liabilities	480470000	USD
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	401446000	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	881916000	USD
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	101481134	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	101481134	shares
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	115998221	shares
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	115998221	shares
CY2012Q3	isis	Research And Development Revenue Under Collaborative Agreements ResearchAndDevelopmentRevenueUnderCollaborativeAgreements	11127000	USD
CY2012Q3	isis	Licensing And Royalty Revenue LicensingAndRoyaltyRevenue	474000	USD
CY2012Q3	us-gaap	Revenues Revenues	11601000	USD
	isis	Research And Development Revenue Under Collaborative Agreements ResearchAndDevelopmentRevenueUnderCollaborativeAgreements	80085000	USD
CY2012Q3	us-gaap	Operating Expenses OperatingExpenses	39647000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	113400000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9281000	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-28046000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-42805000	USD
	us-gaap	Operating Expenses OperatingExpenses	124981000	USD
CY2012Q3	us-gaap	Investment Income Net InvestmentIncomeNet	408000	USD
CY2012Q3	us-gaap	Interest Expense InterestExpense	5937000	USD
CY2012Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4770000	USD
	isis	Research And Development Revenue Under Collaborative Agreements ResearchAndDevelopmentRevenueUnderCollaborativeAgreements	102918000	USD
CY2013Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	175000	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-38345000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	1485000	USD
	us-gaap	Interest Expense InterestExpense	16335000	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	19000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-63545000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4770000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1139000	USD
CY2012Q3	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	-706000	USD
	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	-704000	USD
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-37639000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-62841000	USD
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.63
CY2012Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100680000	shares
CY2012Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100680000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100351000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100351000	shares
	us-gaap	Investment Income Net InvestmentIncomeNet	1400000	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	2073000	USD
CY2013Q3	us-gaap	Revenues Revenues	23585000	USD
	us-gaap	Revenues Revenues	105036000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-31808000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-25505000	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	49090000	USD
	us-gaap	Operating Expenses OperatingExpenses	136844000	USD
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29763000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-42805000	USD
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24570000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-36368000	USD
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2013Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115263000	shares
CY2013Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115263000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	108608000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	108608000	shares
CY2012Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-122000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1616000	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-37761000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-61225000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-34159000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	172581000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	189397000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1033000	USD
	isis	Payments To Acquire Licenses And Other Assets PaymentsToAcquireLicensesAndOtherAssets	2779000	USD
	isis	Purchases Of Strategic Investments PurchasesOfStrategicInvestments	40000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	12964000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-170456000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	7789000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	194689000	USD
	us-gaap	Repayments Of Subordinated Debt RepaymentsOfSubordinatedDebt	163718000	USD
	isis	Proceeds From Equipment Financing Arrangement ProceedsFromEquipmentFinancingArrangement	9100000	USD
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	7579000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	40281000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	173292000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	224397000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	19086000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	131926000	USD
	us-gaap	Interest Paid InterestPaid	5584000	USD
	us-gaap	Interest Paid InterestPaid	3079000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2000	USD
	isis	Noncash Capital And Patent Expenditures NoncashCapitalAndPatentExpenditures	839000	USD
	isis	Noncash Capital And Patent Expenditures NoncashCapitalAndPatentExpenditures	835000	USD
CY2013Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	4935000	USD
	isis	Proceeds From The Sale Of Strategic Investments ProceedsFromTheSaleOfStrategicInvestments	2110000	USD
CY2013Q3	us-gaap	Other Assets Current OtherAssetsCurrent	7372000	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	87273000	USD
CY2013Q3	isis	Licenses Net LicensesNet	5048000	USD
CY2013Q3	isis	Patents Net PatentsNet	20810000	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	256408000	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	84563000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65477000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	17876000	USD
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22535000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	16541000	USD
CY2013Q3	isis	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	5481000	USD
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	8781000	USD
CY2013Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6653000	USD
CY2013Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22283000	USD
CY2013Q3	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	4649000	USD
CY2013Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	55977000	USD
CY2013Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	151006000	USD
CY2013Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	148705000	USD
CY2013Q3	isis	Capital Lease And Other Long Term Borrowings Non Current CapitalLeaseAndOtherLongTermBorrowingsNonCurrent	6384000	USD
CY2013Q3	isis	Long Term Financing Obligation LongTermFinancingObligation	71097000	USD
	us-gaap	Interest Expense InterestExpense	14470000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19827000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	77985000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	303862000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	135130000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1113000	USD
	isis	Payments To Acquire Licenses And Other Assets PaymentsToAcquireLicensesAndOtherAssets	2721000	USD
	isis	Patent Expenses PatentExpenses	3800000	USD
CY2012Q3	isis	Patent Expenses PatentExpenses	988000	USD
	isis	Patent Expenses PatentExpenses	2300000	USD
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	116000	USD
CY2013Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1315643000	USD
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-943334000	USD
CY2013Q3	isis	Research And Development Revenue Under Collaborative Agreements ResearchAndDevelopmentRevenueUnderCollaborativeAgreements	23383000	USD
CY2013Q3	isis	Licensing And Royalty Revenue LicensingAndRoyaltyRevenue	202000	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	45000000	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3430000	USD
CY2013Q3	us-gaap	Investment Income Net InvestmentIncomeNet	434000	USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	4867000	USD
CY2013Q3	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	-5193000	USD
	isis	Licensing And Royalty Revenue LicensingAndRoyaltyRevenue	2118000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	122800000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10241000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	56898000	USD
	isis	Proceeds From Equipment Financing Arrangement ProceedsFromEquipmentFinancingArrangement	2513000	USD
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	8306000	USD
CY2013Q3	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	166000	USD
CY2012Q3	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	376000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax	1100000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax	1100000	USD
CY2013Q3	isis	Patent Expenses PatentExpenses	695000	USD
CY2012Q3	isis	Research Development And Patent Expense ResearchDevelopmentAndPatentExpense	36551000	USD
	isis	Research Development And Patent Expense ResearchDevelopmentAndPatentExpense	115700000	USD
CY2013Q3	isis	Research Development And Patent Expense ResearchDevelopmentAndPatentExpense	45660000	USD
	isis	Research Development And Patent Expense ResearchDevelopmentAndPatentExpense	126603000	USD

Files In Submission

Name	View Source	Status
0001104659-13-081234-index-headers.html	Edgar Link	pending
0001104659-13-081234-index.html	Edgar Link	pending
0001104659-13-081234.txt	Edgar Link	pending
0001104659-13-081234-xbrl.zip	Edgar Link	pending
a13-19600_110q.htm	Edgar Link	pending
a13-19600_1ex10d1.htm	Edgar Link	pending
a13-19600_1ex10d2.htm	Edgar Link	pending
a13-19600_1ex10d3.htm	Edgar Link	pending
a13-19600_1ex10d4.htm	Edgar Link	pending
a13-19600_1ex31d1.htm	Edgar Link	pending
a13-19600_1ex31d2.htm	Edgar Link	pending
a13-19600_1ex32d1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
isis-20130930.xml	Edgar Link	completed
isis-20130930.xsd	Edgar Link	pending
isis-20130930_cal.xml	Edgar Link	unprocessable
isis-20130930_def.xml	Edgar Link	unprocessable
isis-20130930_lab.xml	Edgar Link	unprocessable
isis-20130930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IONS
IONIS PHARMACEUTICALS INC Stock $ions

2013 Q4 Form 10-Q Financial Statement

#000110465913081234 Filed on November 05, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IONS IONIS PHARMACEUTICALS INC Stock $ions

2013 Q4 Form 10-Q Financial Statement

#000110465913081234 Filed on November 05, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IONS
IONIS PHARMACEUTICALS INC Stock $ions